CommercialCoverageMedium impact
08.00.50ae, Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®)
Independence Blue Cross·Oncology, Hematology, Rheumatology·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
The Rituximab infusion and biosimilars policy (08.00.50ae) has been reissued for commercial plans. This is a pharmacy policy update affecting Rituximab (Rituxan), related biosimilars, and Rituximab/Hyaluronidase (Rituxan Hycela) for subcutaneous injection.
Action Required
By October 29, 2025: Billing team should review the updated Rituximab policy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing guidelines for Rituximab infusions and related biosimilars. Update billing procedures and encounter forms accordingly based on the full policy details.